San Diego—A treatment system that uses steam to ablate prostate tissue (Rezum, NxThera, Inc.) can be considered as a first-line therapy for the treatment of lower urinary tract symptoms (LUTS) secondary to BPH, say investigators from a non-randomized multicenter pilot study with 2-year duration of successful outcomes.
Durable improvements in urinary symptoms, peak urinary flow (Qmax), and quality of life were realized in men treated with convective water vapor ablation with no adverse effects on sexual function, reported Christopher Dixon, MD, at the AUA annual meeting in San Diego.
“All of the clinical parameters in this pilot study were improved and durable, in a very clinically significant way,” said Dr. Dixon, a practicing urologist in New York. “In my opinion as a clinical urologist with an academic background and a lot of experience with medical management of BPH, given the overall clinical database with it, I think it is very reasonable to consider this as a first-line therapy for men with clinical BPH.”
The technology used in the study is an office-based transurethral needle ablation (TUNA) procedure based on phase change convective heating, which involves radiofrequency to convert sterile water into steam, and injecting that steam in a controlled fashion into the transition zone to ablate tissue rapidly and efficiently.